Cooley Reps VC Firm On $122M Cancer Medicine Co. Funding
IDRx, a clinical stage biopharmaceutical company that develops precision cancer treatments, announced Tuesday that it nabbed $122 million in a Series A financing led by Cooley LLP-advised Andreessen Horowitz....To view the full article, register now.
Already a subscriber? Click here to view full article